[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @AlfredoM617 Alfredo M Alfredo M posts on X about $vktx, $vik, breakthrough, drone the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::47191740/interactions)  - X Week XXXXX -XX% - X Month XXXXXX +18,556% - X Months XXXXXXX +635% - X Year XXXXXXX +3,589% ### Mentions: XX [#](/creator/twitter::47191740/posts_active)  - X Month XX +714% - X Months XXX +195% - X Year XXX +1,019% ### Followers: XXX [#](/creator/twitter::47191740/followers)  - X Week XXX +2.90% - X Month XXX +11% - X Months XXX +133% - X Year XXX +134% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::47191740/influencer_rank)  ### Social Influence [#](/creator/twitter::47191740/influence) --- **Social category influence** [stocks](/list/stocks) [finance](/list/finance) [cryptocurrencies](/list/cryptocurrencies) [currencies](/list/currencies) [countries](/list/countries) **Social topic influence** [$vktx](/topic/$vktx), [$vik](/topic/$vik), [breakthrough](/topic/breakthrough), [drone](/topic/drone), [weight loss](/topic/weight-loss), [rates](/topic/rates), [titan](/topic/titan), [$ktos](/topic/$ktos), [cash flow](/topic/cash-flow), [$clbt](/topic/$clbt) **Top assets mentioned** [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Viking Holdings Ltd (VIK)](/topic/$vik) [Kratos Defense & Security Solutions, Inc. (KTOS)](/topic/$ktos) [Cellebrite DI Ltd. Class A Ordinary Shares (CLBT)](/topic/$clbt) [Raytheon Technologies Corp (RTX)](/topic/$rtx) [Pfizer, Inc. (PFE)](/topic/$pfe) [Ormeus Ecosystem (ECO)](/topic/$eco) [Eli Lilly and Company (LLY)](/topic/eli-lilly) [Novartis AG (NVS)](/topic/novartis) [Eos Energy Enterprises, Inc. (EOSE)](/topic/$eose) [L3Harris Technologies Inc (LHX)](/topic/$lhx) [Lockheed Martin Corporation (LMT)](/topic/lockheed-martin) [Limitus (LMT)](/topic/$lmt) ### Top Social Posts [#](/creator/twitter::47191740/posts) --- Top posts by engagements in the last XX hours "VK2735: Redefining Incretin Therapy Through Dual Agonism VK2735 is Vikings $VKTX most valuable asset a dual GLP-1/GIP receptor agonist being developed in both injectable and oral forms. It directly challenges Lillys blockbuster tirzepatide (Mounjaro/Zepbound) but with multiple advantages that could make it a best-in-class therapy in obesity and metabolic disease"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944843353129922987) 2025-07-14 19:36:03 UTC XXX followers, XXX engagements "5. Kratos Defense & Security Solutions $KTOS: Jet-powered drone maker nearing mass-production breakthrough Kratos specializes in low-cost jet-powered combat drones like the XQ-58A Valkyrie. This class of aircraft supports the U.S. Air Forces push for loyal wingman drones and could be mass-produced under the Collaborative Combat Aircraft program. Kratos has already secured several prototype and production prep contracts with expectations of a major Valkyrie award soon. It is also involved in the Air Forces OBSS drone development. For investors seeking exposure to the future of aerial combat"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1945069983953735950) 2025-07-15 10:36:36 UTC XXX followers, XXX engagements "Mechanism and Innovation $VKTX Like tirzepatide VK2735 activates both the GLP-1 and GIP receptors. GLP-1 reduces appetite promotes satiety and improves glycemic control. GIP co-agonism can enhance insulin secretion and weight loss further producing additive or synergistic effects. What makes VK2735 unique is its dual-format development a once-weekly injection and a once-daily oral tablet using the same molecular structure. This dual availability is unmatched. It opens a new paradigm: injectable induction therapy followed by oral maintenance keeping patients on the same drug throughout their"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944843354904179008) 2025-07-14 19:36:03 UTC XXX followers, XXX engagements "Cellebrite $CLBT cloud and AI tools are taking off with key products growing over 100%. Defense and intelligence customers are stepping up even as some U.S. federal and Europe deals face delays. Solid cash flow and smart spending keep the company on track for a stronger second half"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1941495878243488222) 2025-07-05 13:54:23 UTC XXX followers, 21.5K engagements "9. RTX Corporation $RTX: Missile and counter-drone juggernaut with global demand RTX formerly Raytheon Technologies is a dominant player in missile systems and counter-drone air defenses. Its Patriot and NASAMS systems have seen soaring demand across NATO countries. RTX is also advancing directed energy weapons and drone-targeting adaptations of its interceptors. Despite recent headwinds in its commercial division the defense segment is strong. With growing drone threats RTX is positioned to generate significant revenue from missile defense and radar solutions"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1945069976609546702) 2025-07-15 10:36:34 UTC XXX followers, 1499 engagements "@tuduni90782 I was targeting the CEO @ $PFE"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944865430440702040) 2025-07-14 21:03:47 UTC XXX followers, XXX engagements "$ECO Q2 2025: Suezmax Rates Surge XX% as Young Fleet and Oil Flows Reshape Tanker Upside Spot Rate Windfall from Tight Supply: $ECO locked in Suezmax spot rates of $60600 per day as OPEC shifts and aging fleets drive scarcity giving its young eco-compliant tankers a pricing edge. Strategic Leverage on Volatility: Full spot exposure and low-cost capital structure position $ECO to capture upside from geopolitical shifts rising asset values and long-haul oil trade demand"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1941978148385521967) 2025-07-06 21:50:45 UTC XXX followers, XXX engagements "Viking Therapeutics ($VKTX): A Deep Dive into a Potential Best-in-Class Metabolic Drug Pipeline Viking Therapeutics $VKTX once viewed as a speculative small-cap biotech is now emerging as a serious contender in the trillion-dollar fight against obesity type X diabetes and liver disease. With its lead asset VK2735 delivering unprecedented efficacy and safety across injectable and oral formulations and its NASH candidate VK2809 showing best-in-class liver and lipid effects Viking may soon force its way into a therapeutic landscape long dominated by Novo Nordisk and Eli Lilly. This article"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944843351410217452) 2025-07-14 19:36:03 UTC XXX followers, 9518 engagements "6. AgEagle Aerial Systems $UAVS: Mini-drone maker transitioning into defense growth mode Originally focused on agricultural drones AgEagle pivoted into tactical systems and secured its largest-ever order with the French Army. Its eBee line of fixed-wing drones is now approved for U.S. military use and is gaining traction among NATO partners. With a small market cap and a recent transition to defense the company has substantial upside if it continues to win contracts. AgEagle is also targeting U.S. Army units positioning itself as a legitimate supplier in the growing mini-drone segment"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1945069982154424516) 2025-07-15 10:36:36 UTC XXX followers, XXX engagements "Efficacy: Among the Best Observed in the Field $VKTX In its 13-week Phase X VENTURE trial VK2735s injectable version delivered up to XXXX% weight loss with XX% of patients achieving XX% weight loss comparable to or better than tirzepatide and clearly outpacing semaglutide (Wegovy). Key highlights: Placebo-adjusted weight loss: XXXX% at XX mg weekly in just XX weeks Progressive loss: No plateau by Week 13; trajectory suggests even higher efficacy with longer dosing Durability: Over XX% of weight lost was retained X weeks after cessation hinting at infrequent maintenance dosing potential"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944843356825346229) 2025-07-14 19:36:04 UTC XXX followers, XXX engagements "Safety and Tolerability $VKTX VK2735 stands out for low incidence of severe gastrointestinal side effects the Achilles heel of most GLP-1 agonists. Across trials: Nausea was common but mild in over two-thirds of cases No severe vomiting with oral or injectable Low discontinuation rates (13% on par with placebo) If these tolerability benefits hold in Phase X VK2735 could become the first widely acceptable GLP-1-based therapy for patients whove struggled with side effects from Wegovy or Mounjaro"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944843360016928916) 2025-07-14 19:36:05 UTC XXX followers, XXX engagements "Competitive Landscape: Scarcity Creates Value $VKTX Only two companies dominate the GLP-1 space today: Novo Nordisk and Eli Lilly. Most other large pharmas including Pfizer Amgen Roche Novartis GSK are either absent from the space or have failed programs. Pfizers oral GLP-1 (danuglipron) was dropped due to side effects Roche paid $2.7B for Carmot which had less mature dual agonists than VK2735 Amgen GSK and others have early-stage programs but no clinical readouts approaching VKTXs This vacuum creates tremendous leverage for Viking. VK2735 is already Phase 3-ready and derisked by data that"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944843365616336939) 2025-07-14 19:36:06 UTC XXX followers, XXX engagements "This US battery company just turned a corner $EOSE EOS Energy makes long-duration batteries that dont use lithium. Think: grid storage that lasts for hours not minutes. Q1 saw a 93-point margin swing as automation kicked in. Theyre not just making more batteries theyre finally making them cheaper"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944857159071682902) 2025-07-14 20:30:55 UTC XXX followers, 1275 engagements "$VKTX Valuation: Undervalued or Deliberately Ignored Despite blockbuster data Viking trades at a fraction of its potential"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944843367310848433) 2025-07-14 19:36:06 UTC XXX followers, XXX engagements "10. L3Harris Technologies $LHX: Electronic warfare and C-UAS leader with rising demand L3Harris combines counter-drone weaponry and secure communications both essential in drone-era conflict. Its VAMPIRE system a mobile drone-killer is being deployed by Ukraine and NATO allies. L3Harris also provides tactical radios EW equipment and newly developed drones for U.S. Army use. As militaries seek fast solutions to drone and EW challenges L3Harris is a capable mid-tier player with attractive valuation and clear growth runway"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1945069974684364965) 2025-07-15 10:36:34 UTC XXX followers, XXX engagements "VK2809: A Potential Breakthrough in NASH and Cardiometabolic Disease $VKTX While VK2735 leads headlines VK2809 deserves its own spotlight. This is a liver-selective thyroid hormone receptor- (TR) agonist developed for nonalcoholic steatohepatitis (NASH) a chronic progressive liver disease with no FDA-approved drug. Phase 2b Results: Arguably Best-in-Class In its 52-week VOYAGE trial VK2809 hit multiple histological and metabolic endpoints: XX% achieved NASH resolution (vs XX% placebo) XX% showed fibrosis improvement (vs XX% placebo) XX% achieved both a rare dual endpoint success LDL and"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944843363745980647) 2025-07-14 19:36:06 UTC XXX followers, XXX engagements "8. Lockheed Martin $LMT: Defense giant with deep exposure to drone and missile tech Lockheed is the top-tier contractor most likely to capture multi-billion dollar drone-related programs. Its efforts include developing collaborative combat aircraft investing in autonomous platforms and expanding missile and air defense systems to counter drones. Though the stocks upside may be more moderate due to its size Lockheed offers stability and broad exposure to nearly every aspect of drone warfare from sensors to swarming systems. It remains a cornerstone of the defense sector"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1945069978467582371) 2025-07-15 10:36:35 UTC XXX followers, XXX engagements "Viking $VKTX Is Not Just Another GLP-1 Play Viking Therapeutics is one of the most underappreciated pipeline stories in biotech. It has: A dual-form GLP-1/GIP agonist that may be best-in-class A NASH drug with market-leading data and lipid benefits A rare disease candidate that could be first-in-class $1B in cash allowing it to go to market alone or with leverage Strong clinical and mechanistic de-risking Multiple paths to monetization including partnership or M&A In short Viking could evolve from a clinical-stage innovator to a dominant metabolic franchise or become the most lucrative buyout"  [@AlfredoM617](/creator/x/AlfredoM617) on [X](/post/tweet/1944843369181561151) 2025-07-14 19:36:07 UTC XXX followers, 1316 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@AlfredoM617 Alfredo M
Alfredo M posts on X about $vktx, $vik, breakthrough, drone the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX -XX%
- X Month XXXXXX +18,556%
- X Months XXXXXXX +635%
- X Year XXXXXXX +3,589%
Mentions: XX #
- X Month XX +714%
- X Months XXX +195%
- X Year XXX +1,019%
Followers: XXX #
- X Week XXX +2.90%
- X Month XXX +11%
- X Months XXX +133%
- X Year XXX +134%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks finance cryptocurrencies currencies countries
Social topic influence $vktx, $vik, breakthrough, drone, weight loss, rates, titan, $ktos, cash flow, $clbt
Top assets mentioned Viking Therapeutics, Inc (VKTX) Viking Holdings Ltd (VIK) Kratos Defense & Security Solutions, Inc. (KTOS) Cellebrite DI Ltd. Class A Ordinary Shares (CLBT) Raytheon Technologies Corp (RTX) Pfizer, Inc. (PFE) Ormeus Ecosystem (ECO) Eli Lilly and Company (LLY) Novartis AG (NVS) Eos Energy Enterprises, Inc. (EOSE) L3Harris Technologies Inc (LHX) Lockheed Martin Corporation (LMT) Limitus (LMT)
Top Social Posts #
Top posts by engagements in the last XX hours
"VK2735: Redefining Incretin Therapy Through Dual Agonism VK2735 is Vikings $VKTX most valuable asset a dual GLP-1/GIP receptor agonist being developed in both injectable and oral forms. It directly challenges Lillys blockbuster tirzepatide (Mounjaro/Zepbound) but with multiple advantages that could make it a best-in-class therapy in obesity and metabolic disease"
@AlfredoM617 on X 2025-07-14 19:36:03 UTC XXX followers, XXX engagements
"5. Kratos Defense & Security Solutions $KTOS: Jet-powered drone maker nearing mass-production breakthrough Kratos specializes in low-cost jet-powered combat drones like the XQ-58A Valkyrie. This class of aircraft supports the U.S. Air Forces push for loyal wingman drones and could be mass-produced under the Collaborative Combat Aircraft program. Kratos has already secured several prototype and production prep contracts with expectations of a major Valkyrie award soon. It is also involved in the Air Forces OBSS drone development. For investors seeking exposure to the future of aerial combat" @AlfredoM617 on X 2025-07-15 10:36:36 UTC XXX followers, XXX engagements
"Mechanism and Innovation $VKTX Like tirzepatide VK2735 activates both the GLP-1 and GIP receptors. GLP-1 reduces appetite promotes satiety and improves glycemic control. GIP co-agonism can enhance insulin secretion and weight loss further producing additive or synergistic effects. What makes VK2735 unique is its dual-format development a once-weekly injection and a once-daily oral tablet using the same molecular structure. This dual availability is unmatched. It opens a new paradigm: injectable induction therapy followed by oral maintenance keeping patients on the same drug throughout their" @AlfredoM617 on X 2025-07-14 19:36:03 UTC XXX followers, XXX engagements
"Cellebrite $CLBT cloud and AI tools are taking off with key products growing over 100%. Defense and intelligence customers are stepping up even as some U.S. federal and Europe deals face delays. Solid cash flow and smart spending keep the company on track for a stronger second half" @AlfredoM617 on X 2025-07-05 13:54:23 UTC XXX followers, 21.5K engagements
"9. RTX Corporation $RTX: Missile and counter-drone juggernaut with global demand RTX formerly Raytheon Technologies is a dominant player in missile systems and counter-drone air defenses. Its Patriot and NASAMS systems have seen soaring demand across NATO countries. RTX is also advancing directed energy weapons and drone-targeting adaptations of its interceptors. Despite recent headwinds in its commercial division the defense segment is strong. With growing drone threats RTX is positioned to generate significant revenue from missile defense and radar solutions" @AlfredoM617 on X 2025-07-15 10:36:34 UTC XXX followers, 1499 engagements
"@tuduni90782 I was targeting the CEO @ $PFE" @AlfredoM617 on X 2025-07-14 21:03:47 UTC XXX followers, XXX engagements
"$ECO Q2 2025: Suezmax Rates Surge XX% as Young Fleet and Oil Flows Reshape Tanker Upside Spot Rate Windfall from Tight Supply: $ECO locked in Suezmax spot rates of $60600 per day as OPEC shifts and aging fleets drive scarcity giving its young eco-compliant tankers a pricing edge. Strategic Leverage on Volatility: Full spot exposure and low-cost capital structure position $ECO to capture upside from geopolitical shifts rising asset values and long-haul oil trade demand" @AlfredoM617 on X 2025-07-06 21:50:45 UTC XXX followers, XXX engagements
"Viking Therapeutics ($VKTX): A Deep Dive into a Potential Best-in-Class Metabolic Drug Pipeline Viking Therapeutics $VKTX once viewed as a speculative small-cap biotech is now emerging as a serious contender in the trillion-dollar fight against obesity type X diabetes and liver disease. With its lead asset VK2735 delivering unprecedented efficacy and safety across injectable and oral formulations and its NASH candidate VK2809 showing best-in-class liver and lipid effects Viking may soon force its way into a therapeutic landscape long dominated by Novo Nordisk and Eli Lilly. This article" @AlfredoM617 on X 2025-07-14 19:36:03 UTC XXX followers, 9518 engagements
"6. AgEagle Aerial Systems $UAVS: Mini-drone maker transitioning into defense growth mode Originally focused on agricultural drones AgEagle pivoted into tactical systems and secured its largest-ever order with the French Army. Its eBee line of fixed-wing drones is now approved for U.S. military use and is gaining traction among NATO partners. With a small market cap and a recent transition to defense the company has substantial upside if it continues to win contracts. AgEagle is also targeting U.S. Army units positioning itself as a legitimate supplier in the growing mini-drone segment" @AlfredoM617 on X 2025-07-15 10:36:36 UTC XXX followers, XXX engagements
"Efficacy: Among the Best Observed in the Field $VKTX In its 13-week Phase X VENTURE trial VK2735s injectable version delivered up to XXXX% weight loss with XX% of patients achieving XX% weight loss comparable to or better than tirzepatide and clearly outpacing semaglutide (Wegovy). Key highlights: Placebo-adjusted weight loss: XXXX% at XX mg weekly in just XX weeks Progressive loss: No plateau by Week 13; trajectory suggests even higher efficacy with longer dosing Durability: Over XX% of weight lost was retained X weeks after cessation hinting at infrequent maintenance dosing potential" @AlfredoM617 on X 2025-07-14 19:36:04 UTC XXX followers, XXX engagements
"Safety and Tolerability $VKTX VK2735 stands out for low incidence of severe gastrointestinal side effects the Achilles heel of most GLP-1 agonists. Across trials: Nausea was common but mild in over two-thirds of cases No severe vomiting with oral or injectable Low discontinuation rates (13% on par with placebo) If these tolerability benefits hold in Phase X VK2735 could become the first widely acceptable GLP-1-based therapy for patients whove struggled with side effects from Wegovy or Mounjaro" @AlfredoM617 on X 2025-07-14 19:36:05 UTC XXX followers, XXX engagements
"Competitive Landscape: Scarcity Creates Value $VKTX Only two companies dominate the GLP-1 space today: Novo Nordisk and Eli Lilly. Most other large pharmas including Pfizer Amgen Roche Novartis GSK are either absent from the space or have failed programs. Pfizers oral GLP-1 (danuglipron) was dropped due to side effects Roche paid $2.7B for Carmot which had less mature dual agonists than VK2735 Amgen GSK and others have early-stage programs but no clinical readouts approaching VKTXs This vacuum creates tremendous leverage for Viking. VK2735 is already Phase 3-ready and derisked by data that" @AlfredoM617 on X 2025-07-14 19:36:06 UTC XXX followers, XXX engagements
"This US battery company just turned a corner $EOSE EOS Energy makes long-duration batteries that dont use lithium. Think: grid storage that lasts for hours not minutes. Q1 saw a 93-point margin swing as automation kicked in. Theyre not just making more batteries theyre finally making them cheaper" @AlfredoM617 on X 2025-07-14 20:30:55 UTC XXX followers, 1275 engagements
"$VKTX Valuation: Undervalued or Deliberately Ignored Despite blockbuster data Viking trades at a fraction of its potential" @AlfredoM617 on X 2025-07-14 19:36:06 UTC XXX followers, XXX engagements
"10. L3Harris Technologies $LHX: Electronic warfare and C-UAS leader with rising demand L3Harris combines counter-drone weaponry and secure communications both essential in drone-era conflict. Its VAMPIRE system a mobile drone-killer is being deployed by Ukraine and NATO allies. L3Harris also provides tactical radios EW equipment and newly developed drones for U.S. Army use. As militaries seek fast solutions to drone and EW challenges L3Harris is a capable mid-tier player with attractive valuation and clear growth runway" @AlfredoM617 on X 2025-07-15 10:36:34 UTC XXX followers, XXX engagements
"VK2809: A Potential Breakthrough in NASH and Cardiometabolic Disease $VKTX While VK2735 leads headlines VK2809 deserves its own spotlight. This is a liver-selective thyroid hormone receptor- (TR) agonist developed for nonalcoholic steatohepatitis (NASH) a chronic progressive liver disease with no FDA-approved drug. Phase 2b Results: Arguably Best-in-Class In its 52-week VOYAGE trial VK2809 hit multiple histological and metabolic endpoints: XX% achieved NASH resolution (vs XX% placebo) XX% showed fibrosis improvement (vs XX% placebo) XX% achieved both a rare dual endpoint success LDL and" @AlfredoM617 on X 2025-07-14 19:36:06 UTC XXX followers, XXX engagements
"8. Lockheed Martin $LMT: Defense giant with deep exposure to drone and missile tech Lockheed is the top-tier contractor most likely to capture multi-billion dollar drone-related programs. Its efforts include developing collaborative combat aircraft investing in autonomous platforms and expanding missile and air defense systems to counter drones. Though the stocks upside may be more moderate due to its size Lockheed offers stability and broad exposure to nearly every aspect of drone warfare from sensors to swarming systems. It remains a cornerstone of the defense sector" @AlfredoM617 on X 2025-07-15 10:36:35 UTC XXX followers, XXX engagements
"Viking $VKTX Is Not Just Another GLP-1 Play Viking Therapeutics is one of the most underappreciated pipeline stories in biotech. It has: A dual-form GLP-1/GIP agonist that may be best-in-class A NASH drug with market-leading data and lipid benefits A rare disease candidate that could be first-in-class $1B in cash allowing it to go to market alone or with leverage Strong clinical and mechanistic de-risking Multiple paths to monetization including partnership or M&A In short Viking could evolve from a clinical-stage innovator to a dominant metabolic franchise or become the most lucrative buyout" @AlfredoM617 on X 2025-07-14 19:36:07 UTC XXX followers, 1316 engagements